IO Biotech presents three posters at SITC meeting

IO Biotech announced three poster presentations at the Society for Immunotherapy of Cancer’s 38th Annual Meeting, SITC, being held in San Diego, California from November 1-5, 2023. “The data presented provide clear evidence that our immune modulating vaccines, developed based on our T-win technology platform, impact several immune escape mechanisms as elegantly exemplified in abstract #1468,” said Mai-Britt Zocca, PhD, President and Chief Executive Officer of IO Biotech. “The data in this poster demonstrate enhanced in vivo anti-tumor effect when IDO and PD-L1 vaccines are co-administered in these models, further supporting the clinical observations regarding our lead investigational therapeutic vaccine candidate, IO102-IO103, which targets IDO and PD-L1. Data from clinical trials of IO102-IO103 administered with a PD-1 inhibitor demonstrated enhanced anti-tumor activity in multiple tumor types, including metastatic melanoma, non-small cell lung cancer and squamous cell cancer of the head and neck.”